Back

Guardant Health wins FDA approval for Guardant360 CDx with AstraZeneca’s ETCAMAH

Verifying
  • Guardant Health announced FDA approval of Guardant360 CDx for AstraZeneca’s ETCAMAH.
  • The test is approved as a companion diagnostic for camizestrant in advanced breast cancer.
  • ETCAMAH is AstraZeneca’s brand name for camizestrant, according to the announcement.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Guardant Health wins FDA approval for Guardant360 CDx with AstraZeneca’s ETCAMAH - CoinPost Terminal